By Russell Pearlman, originally published in issue 35 of Briefings Magazine, and posted on KornFerry.com on May 15, 2018. Kurt Graves had just heard from multiple investors in Intarcia Therapeutics, the pharmaceutical firm he runs, asking him a single question: Why...